Due to the COVID-19 outbreak, the health consciousness of the whole society has been raised, bringing about a new round of development of the comprehensive healthcare industry. Liangjiang New Area has taken measures to prioritize the high-quality development of the comprehensive healthcare industry, meet the needs of the people and the economic and social development, develop the biomedicine industry and promote the high-quality development of the comprehensive healthcare industry.
At the online launching conference of technological anti-epidemic products in Liangjiang New Area held on March 20, besides biomedical enterprises, many other technology enterprises launched their high-tech intelligent anti-epidemic products, which involved the comprehensive healthcare industry. Through live streaming, Liangjiang New Area created opportunities for many enterprises to introduce their cool tech anti-epidemic products to the country.
In addition to the domestic market, Liangjiang-based enterprises are also actively exploiting overseas markets. Recently, four kinds of novel coronavirus rapid detection reagents produced by Chongqing iSIA Biotechnology Co., Ltd., a Liangjiang-based enterprise, were approved with CE certificate, which means they can be sold to most countries and regions in the world, to provide quick, accurate and efficient detection method for global COVID-19 prevention and control.
As a biomedical, industrial park supported by Chongqing Municipality and Liangjiang New Area, Dadi Enterprise Park will build an upgrading and expansion area: Dadi International Life Science Park. Once completed, the science park, with a planned area of over 26.7 hectares and a building area of 500,000 square meters, will accelerate the establishment of a technology research and development platform, a biotechnology pharmaceutical industry base, and intelligent medical equipment innovation and manufacturing base, to build a complete closed-loop ecological industrial chain.
At the online signing of key investment promotion projects for biomedicine development held in Liangjiang New Area on March 14, seven projects were contracted, with a total investment of RMB 8.318 billion.
Covering biotechnology, the building of a tumor organ bank, medical detection, disease screening, and treatment, the seven projects will further improve Liangjiang’s biomedicine industry chain, which will contribute to accelerating the growth of Chongqing’s comprehensive healthcare industry.
Before that, some biomedicine projects that Liangjiang introduced through online signing had been put into operation. The first production line of LyncMed’s healthcare project has been put into operation on March 9, and other production lines of medical masks (including medical-surgical masks and N95 masks) will be completed and put into operation by June, achieving a daily output of 2 million masks by then. In addition, ten protective suit and isolation gown production lines of that project are scheduled to be completed and put into operation within this year, with a daily output of no less than 5,000 sets.
Another project, Norco Med’s new KN95 mask project, produces new KN95 masks with new nanometer materials on a trial basis. Compared with conventional masks, this kind of KN95 mask is lighter and thinner, halving the respiratory resistance from that of ordinary protective masks on the premise of ensuring the filtration function.
According to the relevant person in charge of the comprehensive healthcare industry investment authority of Liangjiang New Area, Liangjiang will further promote the implementation and commercial transformation of high-end technologies and products and strengthen clinical research and application scenario building. Moreover, on the basis of expanding the industrial cluster, Liangjiang will make deployments to develop cutting-edge technologies such as genetic engineering and 3D bioprinting, and digital health fields such as Internet healthcare and healthcare big data platform, so as to achieve integrated development of different industries.
For any inquiries, please email email@example.com